Evidence map›Paper›PMID 36860165›Full record

ReviewJournal of leukocyte biology2023

Effects of epigenetic therapy on natural killer cell function and development in hematologic malignancy.

Matthew R Lordo, Andrew R Stiff, Christopher C Oakes, Bethany L Mundy-Bosse

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of leukocyte biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Matthew R LordoComprehensive Cancer Center, The Ohio State University, 460 W. 10th Avenue, Columbus, OH 43210, USA.
Andrew R StiffComprehensive Cancer Center, The Ohio State University, 460 W. 10th Avenue, Columbus, OH 43210, USA.
Christopher C OakesComprehensive Cancer Center, The Ohio State University, 460 W. 10th Avenue, Columbus, OH 43210, USA.
Bethany L Mundy-BosseComprehensive Cancer Center, The Ohio State University, 460 W. 10th Avenue, Columbus, OH 43210, USA.
The Ohio State University Wexner Medical Center · USThe Ohio State University · US

Funding

Tumor ImmunologyT32CA090223 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E. · 2002 to 2023
$4.1M
Dysregulation of Innate Lymphoid Immunity in Acute Myeloid LeukemiaR01CA255860 · NCI · OHIO STATE UNIVERSITY · PI MUNDY-BOSSE, BETHANY, OAKES, CHRISTOPHER C. · 2021 to 2025
$2.5M
Group 1 Innate Lymphoid Cell Dysregulation in Acute Myeloid LeukemiaF30CA250244 · NCI · OHIO STATE UNIVERSITY · PI LORDO, MATTHEW · 2022 to 2025
$193k
NCI NIH HHS F30 CA250244NCI NIH HHS R01 CA255860NCI NIH HHS T32 CA090223
6 · The paper itself

Abstract

Epigenetic therapy is an emerging field in the treatment of human cancer, including hematologic malignancies. This class of therapeutic agents approved by the US Food and Drug Administration for cancer treatment includes DNA hypomethylating agents, histone deacetylase inhibitors, IDH1/2 inhibitors, EZH2 inhibitors, and numerous preclinical targets/agents. Most studies measuring the biological effects of epigenetic therapy focus their attention on either their direct cytotoxic effects on malignant cells or their effects on modifying tumor cell antigen expression, exposing them to immune surveillance mechanisms. However, a growing body of evidence suggests that epigenetic therapy also has effects on the development and function of the immune system, including natural killer cells, which can alter their response to cancer cells. In this review, we summarize the body of literature studying the effects of different classes of epigenetic therapy on the development and/or function of natural killer cells.

Indexed as

Antineoplastic AgentsHematologic NeoplasmsEpigenesis, GeneticHistone Deacetylase InhibitorsHumansKiller Cells, NaturalAntineoplastic AgentsHistone Deacetylase InhibitorsALLAMLepigenetic therapyleukemianatural killer cellNK cell

Identifiers

PMID36860165
PMCPMC10443672
OpenAlexW4322757850

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.